D-W Wu

发表

TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells

H. Lee, Hsu-Shan Huang, Tsung-Chih Chen, 2016, Cell Death and Disease.

Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression

Y. Cheng, C-Y Chen, T. Wu, 2014, Oncogene.

FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction

Y. Cheng, C-Y Chen, T. Wu, 2017, Oncogene.

FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction

Y. Cheng, C-Y Chen, T. Wu, 2014, Oncogene.

DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer

Y. Cheng, C-Y Chen, H. Lee, 2014, Oncogene.

Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability

C-Y Chen, H. Lee, De-Wei Wu, 2016, Oncogene.

Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer

H. Lee, C-C Huang, D-W Wu, 2014, Cell Death and Differentiation.

c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT

Y. Cheng, C-Y Chen, H. Lee, 2014, Oncogene.

FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction

Y. Cheng, C-Y Chen, T. Wu, 2015, Oncogene.